The present invention provides methods of preventing or reducing oxytocin-mediated action by using a thiazolidinedione, such as troglitazone, or thiazolidinedione-like compounds. These methods describe the employment of these compounds alone or in combination with at least one other agent, such as a tocolytic agent. This offers a novel therapeutic regimen for the treatment of oxytocin-mediated actions, for example induction of uterine contractions, prostaglandin release, and milk letdown. Accord...

The present invention is directed toward the use of the drug Troglitazone and related thiazolidinedione compounds in the treatment of the climacteric and cancer. This use is based on the novel discovery that Troglitazone inhibits steroidogenesis in granulosa cell cultures. This activity is believed to result from the ability of thiazolidinedione derivatives to act as a ligand for the orphan steroid receptor peroxisome proliferator-activated receptor gamma (PPARgamma). Troglitazone and related co...

The present invention provides methods of preventing or reducing oxytocin-mediated action by using a thiazolidinedione, such as troglitazone, or thiazolidinedione-like compounds. These methods describe the employment of these compounds alone or in combination with at least one other agent, such as a tocolytic agent. This offers a novel therapeutic regimen for the treatment of oxytocin-mediated actions, for example induction of uterine contractions, prostaglandin release, and milk letdown. Accord...

The present invention provides methods of preventing or reducing oxytocin- mediated action by using a thiazolidinedione, such as troglitazone, or thiazolidinedione-like compounds. These methods describe the employment of these compounds alone or in combination with at least one other agent, such as a tocolytic agent. This offers a novel therapeutic regimen for the treatment of oxytocin-mediated actions, for example induction of uterine contractions, prostaglandin release, and milk letdown. Accor...

A purpose of the present invention is to identify and/or develop nontoxic or low toxic chemotherapeutic regiments to treat cancer. Prototype cells tested are derived from an osteosarcoma from an eleven year girl who died after aggressive chemotherapeutic treatment with adriamycin, vincristine, cytoxan, and aramycin-C. The inventive steps described herein include demonstrating that troglitazone inhibits cell proliferation in human osteosarcoma cells, the presence of functional PPAR- gamma in such...

The present invention is directed to methods and compositions for preventing beta -cell destruction and for ameliorating obesity related NIDDM. More particularly the present inventors have found that beta -cell destruction occurs in obesity related NIDDM through the action of ceramides. The present invention suggests that ceramides mediate their cytotocic influence through increased NO production.

The present invention is directed toward the use of the drug Troglitazone and related thiazolidinedione compounds in the treatment of the climacteric and cancer. This use is based on the novel discovery that Troglitazone inhibits steroidogenesis in granulosa cell cultures. This activity is believed to result from the ability of thiazolidinedione derivatives to act as a ligand for the orphan steroid receptor peroxisome proliferator-activated receptor gamma (PPAR gamma ). Troglitazone and related ...

The present invention is directed toward the use of the drug Troglitazone and related thiazolidinedione compounds in the treatment of the climacteric and cancer. This use is based on the novel discovery that Troglitazone inhibits steroidogenesis in granulosa cell cultures. This activity is believed to result from the ability of thiazolidinedione derivatives to act as a ligand for the orphan steroid receptor peroxisome proliferator-activated receptor gamma (PPAR gamma ). Troglitazone and related ...

The present invention is directed toward the use of the drug Troglitazone and related thiazolidinedione compounds in the treatment of the climacteric and cancer. This use is based on the novel discovery that Troglitazone inhibits steroidogenesis in granulosa cell cultures. This activity is believed to result from the ability of thiazolidinedione derivatives to act as a ligand for the orphan steroid receptor peroxisome proliferator-activated receptor gamma (PPAR.gamma.). Troglitazone and related ...